Recursion Pharmaceuticals (NasdaqGS:RXRX) Surges 6% Following US$500 Million Follow-On Equity Offering
Recursion Pharmaceuticals (NasdaqGS:RXRX) recently announced a $500 million Follow-on Equity Offering and revealed mixed earnings results for Q4 2024, which showed declining quarterly sales and ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 28, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported ...
Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says
Recursion Pharmaceuticals is a leader in TechBio with potential to bring in $200M in near-term milestones and $20B in future ...
JD Supra14h
From personalization to supply chain optimization: How AI is shaping deals outside the tech arena
Investors are ramping up AI-related M&A to secure cutting-edge capabilities and market-beating returns, but high valuations and open-source ...